Sec Form 3 Filing - Schneyer Mark C. @ ACADIA PHARMACEUTICALS INC - 2021-12-09

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Schneyer Mark C. 2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400 3. Date of Earliest Transaction (MM/DD/YY) 12/09/2021 (Street) SAN DIEGO, CA92130 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 1,303 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 46.81 ( 1 ) 06/07/2030 Common Stock 41,066 D Employee Stock Option (Right to Buy) $ 49.74 ( 2 ) 02/22/2031 Common Stock 19,927 D Restricted Stock Units ( 4 ) ( 3 ) ( 3 ) Common Stock 5,679 D Restricted Stock Units ( 4 ) ( 5 ) ( 5 ) Common Stock 5,411 D Restricted Stock Units ( 4 ) ( 6 ) ( 6 ) Common Stock 39,651 D Restricted Stock Units ( 4 ) ( 7 ) ( 7 ) Common Stock 39,651 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Schneyer Mark C. C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO, CA92130 Chief Financial Officer Signatures /s/ Austin D. Kim, Attorney-in-Fact 12/20/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )25% of the shares subject to the Stock Option vested and became exercisable on June 8, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. ( 2 )25% of the shares subject to the Stock Option vest and become exercisable on February 23, 2022, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. ( 3 )One-third of the shares subject to the restricted stock units vest on each of June 8, 2022, June 8, 2023 and June 8, 2024. ( 4 )Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. ( 5 )The restricted stock units vest in four equal annual installments beginning February 23, 2022. ( 6 )The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. ( 7 )The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.